SOUTH SAN FRANCISCO, Calif., Nov. 12, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (KBIO) a biopharmaceutical company with a portfolio of patient-targeted, first-in-class, monoclonal antibodies (mAbs) to treat severe respiratory diseases and cancer, announced today its corporate highlights and financial results for the third quarter ending September 30, 2013.
Help employers find you! Check out all the jobs and post your resume.
